21 / 60
19
PROGRAMME & EXHIBITION GUIDE |
SCIENTIFIC PROGRAMME
16:10 Pivotal trial results and EU comparison of 99mTc-Tilmanocept in sentinel
node biopsy in head and neck cancer patients
R. De Bree (The Netherlands), J. Buscombe, S.Y. Lai, A. Agrawal,
C. Reininger, F. Civantos
OC-041
16:20 Definitive chemoradiotherapy: An alternative to surgery in stage III/IV
squamous cell carcinoma of the oral cavity?
M.H. Bertke (USA), N.E. Dunlap, M.J. Amsbaugh, C.L. Silverman,
J.M. Bumpous, K.L. Potts, R.A. Redman, J.N. Shaughnessy
OC-042
16:30 Morbidity and functional outcomes of different transoral supraglottic
resections
C. Piazza (Italy), F. Del Bon, D. Barbieri, P. Grazioli, P. Perotti, A. Paderno,
G. Mazza, B. Frittoli, P. Nicolai, G. Peretti
OC-043
16:40 ‘Cure’ is a realistic goal in HPV-related oropharyngeal cancer with
oligometastasis
S. Huang (Canada), J. Waldron, W. Xu, J. Ringash, A. Bayley, A. Hope,
J. Kim, J. Cho, M. Giuliani, B. O’Sullivan
OC-044
16:50 Best practices for supportive care during chemo-radiotherapy in head and
neck cancer patients
P. Bossi (Italy), E. Russi, G. Numico, J.B. Vermorken, B. Murphy,
J. Raber-Durlacher, J.A. Langendijk, C. Rognoni, S. Quaglini, L. Licitra
OC-045
Debate
THIS HOUSE BELIEVES THAT RADIOTHERAPY SHOULD BE COMBINED
WITH CETUXIMAB BUT NOTWITH CHEMOTHERAPY IN PATIENTS WITH
LOCALLY ADVANCED HPV POSITIVE OROPHARYGEAL CANCER
17:00 - 18:00
Chair: J. Bourhis (Switzerland)
17:00 For the motion
Speaker: K. Harrington (United Kingdom)
17:15 Against the motion
Speaker: J. Overgaard (Denmark)